These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25773281)

  • 1. Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter.
    Ryder RE
    Diabet Med; 2015 Apr; 32(4):438-9. PubMed ID: 25773281
    [No Abstract]   [Full Text] [Related]  

  • 2. Pioglitazone: are rumours of its death exaggerated?
    Gale EA
    Diabet Med; 2015 Apr; 32(4):431-7. PubMed ID: 25773280
    [No Abstract]   [Full Text] [Related]  

  • 3. GLP-1-based therapies: the dilemma of uncertainty.
    Spranger J; Gundert-Remy U; Stammschulte T
    Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
    [No Abstract]   [Full Text] [Related]  

  • 4. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 5. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
    de Heer J; Göke B
    Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperplasia from GLP-1 drugs is "not a surprise," say researchers.
    Cohen D
    BMJ; 2013 Mar; 346():f2025. PubMed ID: 23535260
    [No Abstract]   [Full Text] [Related]  

  • 8. Incretin-mimetic therapies and pancreatic disease: a review of observational data.
    Suarez EA; Koro CE; Christian JB; Spector AD; Araujo AB; Abraham S
    Curr Med Res Opin; 2014 Dec; 30(12):2471-81. PubMed ID: 25180611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?
    Deane AM; Horowitz M
    Diabetes Care; 2014 Feb; 37(2):e40-1. PubMed ID: 24459168
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?
    Schwartz S; Defronzo RA
    Diabetes Care; 2014 Feb; 37(2):e42. PubMed ID: 24459169
    [No Abstract]   [Full Text] [Related]  

  • 11. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
    Angeli FS; Shannon RP
    Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.
    Kmietowicz Z
    BMJ; 2013 Jun; 346():f3782. PubMed ID: 23757752
    [No Abstract]   [Full Text] [Related]  

  • 13. Incretins and pancreatitis--what happens next? A personal viewpoint.
    Robson J
    Diabet Med; 2013 Oct; 30(10):1156-9. PubMed ID: 24073726
    [No Abstract]   [Full Text] [Related]  

  • 14. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
    Moses A
    BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
    [No Abstract]   [Full Text] [Related]  

  • 16. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
    Aroda VR; Ratner R
    Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
    Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
    N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
    [No Abstract]   [Full Text] [Related]  

  • 18. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
    Chalmer T; Almdal TP; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of incretin based drugs.
    Montori VM
    BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.